Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $181,000.

  • Kymera Therapeutics' Capital Expenditures rose 195.77% to $181,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 90.31%. This contributed to the annual value of $12.8 million for FY2024, which is 62.77% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Capital Expenditures of $181,000 as of Q3 2025, which was down 73.96% from $695,000 recorded in Q2 2025.
  • Kymera Therapeutics' Capital Expenditures' 5-year high stood at $11.6 million during Q4 2023, with a 5-year trough of -$189,000 in Q3 2024.
  • For the 3-year period, Kymera Therapeutics' Capital Expenditures averaged around $4.4 million, with its median value being $4.0 million (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 3,016.62% in 2023, then slumped by 102.34% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Capital Expenditures (Quarterly) stood at $501,000 in 2021, then fell by 25.55% to $373,000 in 2022, then soared by 3,016.62% to $11.6 million in 2023, then tumbled by 91.95% to $936,000 in 2024, then spiked by 195.77% to $181,000 in 2025.
  • Its last three reported values are $181,000 in Q3 2025, $695,000 for Q2 2025, and $467,000 during Q1 2025.